Prestige Biologics Co. Ltd.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for… Read more
Prestige Biologics Co. Ltd. (334970) - Total Assets
Latest total assets as of September 2025: ₩269.41 Billion KRW
Based on the latest financial reports, Prestige Biologics Co. Ltd. (334970) holds total assets worth ₩269.41 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prestige Biologics Co. Ltd. - Total Assets Trend (2018–2024)
This chart illustrates how Prestige Biologics Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Prestige Biologics Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Prestige Biologics Co. Ltd.'s total assets of ₩269.41 Billion consist of 15.1% current assets and 84.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.6% |
| Accounts Receivable | ₩438.43 Million | 0.2% |
| Inventory | ₩26.91 Billion | 10.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.03 Billion | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Prestige Biologics Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prestige Biologics Co. Ltd.'s current assets represent 15.1% of total assets in 2024, a decrease from 50.0% in 2018.
- Cash Position: Cash and equivalents constituted 0.6% of total assets in 2024, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2018.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Prestige Biologics Co. Ltd. Competitors by Total Assets
Key competitors of Prestige Biologics Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AGP Ltd
KAR:AGP
|
Pakistan | PKRs28.27 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620
|
Korea | ₩269.00 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
Korea | ₩246.13 Billion |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩291.47 Billion |
|
WooGene B&G Co. Ltd
KQ:018620
|
Korea | ₩117.10 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
Prestige Biologics Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Prestige Biologics Co. Ltd. generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Prestige Biologics Co. Ltd. is currently not profitable relative to its asset base.
Prestige Biologics Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.35 | 0.70 | 0.41 |
| Quick Ratio | 0.08 | 0.56 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-76.42 Billion | ₩ -37.60 Billion | ₩ -22.37 Billion |
Prestige Biologics Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Prestige Biologics Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.6% |
| Total Assets | ₩270.29 Billion |
| Market Capitalization | $35.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prestige Biologics Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Prestige Biologics Co. Ltd.'s assets decreased by 6.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prestige Biologics Co. Ltd. (2018–2024)
The table below shows the annual total assets of Prestige Biologics Co. Ltd. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩270.29 Billion | -6.61% |
| 2023-12-31 | ₩289.41 Billion | +12.14% |
| 2022-12-31 | ₩258.08 Billion | +24.82% |
| 2021-12-31 | ₩206.77 Billion | +311.62% |
| 2020-12-31 | ₩50.23 Billion | -30.33% |
| 2019-12-31 | ₩72.10 Billion | -1.46% |
| 2018-12-31 | ₩73.17 Billion | -- |